{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T23:13:59Z","timestamp":1789859639504,"version":"4.0.1"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007316","name":"Division of Cancer Prevention, National Cancer Institute","doi-asserted-by":"publisher","award":["5R01CA172880"],"award-info":[{"award-number":["5R01CA172880"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Houston Veterans Affairs Health Services Research Center of Innovations","award":["CIN13-413"],"award-info":[{"award-number":["CIN13-413"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160097"],"award-info":[{"award-number":["RP160097"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Pancreatic cancer is the fourth leading cause of cancer death. Soluble receptor for glycation end products (sRAGE), which is modulated by anti-hypertensive (HT) medications, has been inversely associated with pancreatic cancer. However, the association between commonly used anti-HT medications and risk of pancreatic cancer is unknown. A total of 145,551 postmenopausal women from the Women Health Initiative (WHI) Study were included in analysis. Use of angiotensin converting enzyme inhibitors (ACEi), \u03b2-blockers, calcium channel blockers (CCBs) and diuretics was ascertained at baseline (1993\u20131998). Baseline sRAGE levels were measured among a subset of 2104 participants using an immunoassay. Multivariable Cox proportional hazard regression model was performed to estimate hazard ratios (HRs) and its 95% confidence intervals (CIs) for pancreatic cancer in association with anti-HT medications. Increased risk of pancreatic cancer was found among users of short-acting CCB (HR = 1.66, 95% CI: 1.20\u20132.28) and long-term (\u22653 years) users of short-acting CCB (HR = 2.07, 95% CI: 1.42\u20133.02) compared to users of other anti-HT medications. Average sRAGE levels were lower in short-acting CCB users than users of other anti-HT medications (1173 versus 1454 pg\/mL, p = 0.038). Non-statistically significant reduced risk of pancreatic cancer was found among users of \u03b2-blockers (HR = 0.80, 95% CI: 0.60\u20131.07). Average sRAGE levels were higher in \u03b2-blockers users than users of other anti-HT medications (1692 versus 1454 pg\/mL, p &gt; 0.05). Future studies are warranted to confirm these findings and elucidate potential mechanisms by which anti-HT medications influence development of pancreatic cancer.<\/jats:p>","DOI":"10.3390\/jcm7080197","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T03:03:15Z","timestamp":1533265395000},"page":"197","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Anti-Hypertensive Medication Use, Soluble Receptor for Glycation End Products and Risk of Pancreatic Cancer in the Women\u2019s Health Initiative Study"],"prefix":"10.3390","volume":"7","author":[{"given":"Zhensheng","family":"Wang","sequence":"first","affiliation":[{"name":"Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"White","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Texas Medical Center Digestive Disease Center, Houston, TX 77030, USA"},{"name":"Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Hoogeveen","sequence":"additional","affiliation":[{"name":"Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Whitsel","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology and Medicine, Gillings School of Global Public Health and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richardson","sequence":"additional","affiliation":[{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Virani","sequence":"additional","affiliation":[{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Garcia","sequence":"additional","affiliation":[{"name":"Geriatric Research Education and Clinical Center (GRECC), Puget Sound Department of Veterans Affairs Medical Center, Seattle, WA 98108, USA"},{"name":"Section of Endocrinology, Department of Medicine, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem","family":"El-Serag","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Texas Medical Center Digestive Disease Center, Houston, TX 77030, USA"},{"name":"Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiao","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"},{"name":"Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Texas Medical Center Digestive Disease Center, Houston, TX 77030, USA"},{"name":"Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, TX 77030, USA"},{"name":"Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"ref_1","unstructured":"National Center for Health Statistics (2018, June 06). Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK367640."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.canlet.2016.07.022","article-title":"Modifiable and non-modifiable risk factors for pancreatic cancer: A review","volume":"381","author":"Midha","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_3","unstructured":"Yoon, S.S., Fryar, C.D., and Carroll, M.D. (2015). Hypertension Prevalence and Control among Adults: United States, 2011\u20132014."},{"key":"ref_4","unstructured":"(2018, June 06). National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1158\/0008-5472.CAN-10-2573","article-title":"Evidence that serum levels of the soluble receptor for advanced glycation end products are inversely associated with pancreatic cancer risk: A prospective study","volume":"71","author":"Jiao","year":"2011","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cam4.1426","article-title":"A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women","volume":"7","author":"White","year":"2018","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11739-009-0300-1","article-title":"Soluble forms of RAGE in internal medicine","volume":"4","author":"Vazzana","year":"2009","journal-title":"Intern. Emerg. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/157016110790226642","article-title":"Soluble RAGE-modulating drugs: State-of-the-art and future perspectives for targeting vascular inflammation","volume":"8","author":"Lanati","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/jcpt.12139","article-title":"Effects of enalapril\/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients","volume":"39","author":"Derosa","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejphar.2009.10.034","article-title":"Beta2-adrenoceptor stimulation inhibits advanced glycation end products-induced adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells","volume":"627","author":"Takahashi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbrc.2010.06.093","article-title":"Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor\u2013gamma activation","volume":"398","author":"Matsui","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1047-2797(03)00041-3","article-title":"Baseline Monograph\u2014Foreword","volume":"13","author":"Rossouw","year":"2003","journal-title":"Ann. Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","article-title":"Design of the Women\u2019s Health Initiative clinical trial and observational study. The Women\u2019s Health Initiative Study Group","volume":"19","author":"Anderson","year":"1998","journal-title":"Control. Clin. Trials"},{"key":"ref_15","unstructured":"(2018, February 08). Women\u2019s Health Intitiative (WHI) Dataset Documentation. Available online: https:\/\/www.whi.org\/researchers\/data\/WhiDataDict\/f44_ctos_inv.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S1047-2797(03)00048-6","article-title":"WHI Morbidity and Mortality Committee Outcomes ascertainment and adjudication methods in the Women\u2019s Health Initiative","volume":"13","author":"Curb","year":"2003","journal-title":"Ann. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1047-2797(03)00043-7","article-title":"Implementation of the Women\u2019s Health Initiative study design","volume":"13","author":"Anderson","year":"2003","journal-title":"Ann. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canep.2016.04.004","article-title":"A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women","volume":"42","author":"Chen","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_20","unstructured":"(2018, May 17). Analysis of Survival Data|Taylor & Francis Group. Available online: https:\/\/www.taylorfrancis.com\/books\/9781351466615."},{"key":"ref_21","first-page":"626","article-title":"Rectangular confidence regions for the means of multivariate normal distributions","volume":"62","year":"1967","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCOUTCOMES.113.000359","article-title":"Propensity score methods for confounding control in nonexperimental research","volume":"6","author":"Brookhart","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","article-title":"Calcium channel blockers","volume":"13","author":"Elliott","year":"2011","journal-title":"J. Clin. Hypertens. Greenwich Conn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/CAD.0b013e32832bd1e3","article-title":"Prevention of pancreatic cancer by the beta-blocker propranolol","volume":"20","author":"Schuller","year":"2009","journal-title":"Anticancer Drugs"},{"key":"ref_25","first-page":"584","article-title":"Beta-adrenoceptor action on pancreatic cancer cell proliferation and tumor growth in mice","volume":"59","author":"Lin","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00006676-199403000-00009","article-title":"Inhibitory effect of calcium channel blockers on growth of pancreatic cancer cells","volume":"9","author":"Sato","year":"1994","journal-title":"Pancreas"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-4598-10-146","article-title":"\u03b22-adrenoceptor blockage induces G1\/S phase arrest and apoptosis in pancreatic cancer cells via Ras\/Akt\/NF\u03baB pathway","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1681\/ASN.2005010062","article-title":"Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy","volume":"16","author":"Forbes","year":"2005","journal-title":"JASN"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2016.375","article-title":"The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer","volume":"116","author":"Mandilaras","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.HYP.36.5.780","article-title":"Hypertension and its treatment in postmenopausal women: Baseline data from the Women\u2019s Health Initiative","volume":"36","author":"Wassertheil","year":"2000","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jama.1996.03530300007004","article-title":"FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards","volume":"275","author":"Marwick","year":"1996","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chou, C.L., Chou, C.Y., Hsu, C.C., Chou, Y.C., Chen, T.J., and Chou, L.F. (2014). Old habits die hard: A nationwide utilization study of short-acting nifedipine in Taiwan. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091858"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: Lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am. J. Epidemiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/8\/197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:16:06Z","timestamp":1760195766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/7\/8\/197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["jcm7080197"],"URL":"https:\/\/doi.org\/10.3390\/jcm7080197","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]}}}